Quantitative prediction of drug-drug interactions by PBPK model using the in vivo Ki values

被引：0
|
作者：
Kobashi, Akiko [1 ]
Ciloy, Jose Martin [1 ]
Matsushita, Mayumi [1 ]
Maeda, Kazuya [2 ]
Ito, Kiyomi [3 ]
机构：
[1] Fujitsu Kyushu Syst Ltd, Fukuoka, Japan
[2] Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Mol Pharmacokinet, Tokyo, Japan
[3] Musashino Univ, Pharmaceut Sci Res Inst, Tokyo, Japan
来源：
DRUG METABOLISM REVIEWS | 2015年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P160
引用
收藏
页码：113 / 113
页数：1
相关论文
共 50 条
  • [41] QSAR Modeling and Prediction of Drug-Drug Interactions
    Zakharov, Alexey V.
    Varlamova, Ekaterina V.
    Lagunin, Alexey A.
    Dmitriev, Alexander V.
    Muratov, Eugene N.
    Fourches, Denis
    Kuz'min, Victor E.
    Poroikov, Vladimir V.
    Tropsha, Alexander
    Nicklaus, Marc C.
    MOLECULAR PHARMACEUTICS, 2016, 13 (02) : 545 - 556
  • [42] PBPK MODELING OF TRANSPORTER-RELATED DRUG-DRUG INTERACTIONS INVOLVING ERYTHROMYCIN
    Fraczkiewicz, Grace
    Fraczkiewicz, Grazyna
    Chaudhuri, Siladitya R.
    Lukacova, Viera
    Bolger, Michael B.
    Woltosz, Walter S.
    DRUG METABOLISM REVIEWS, 2012, 44 : 71 - 72
  • [43] Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label (vol 7, pg 321, 2018)
    Reddy, Venkatesh Pilla
    Walker, Michael
    Sharma, Pradeep
    Ballard, Peter
    Vishwanathan, Karthick
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2019, 8 (03): : 188 - 189
  • [44] ANALYSIS OF DRUG-DRUG INTERACTIONS BETWEEN CERIVASTATIN AND INTERACTING DRUGS, CYCLOSPORINE A AND GEMFIBROZIL, USING PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL
    Kim, Soo-Jin
    Yao, Yoshiaki
    Yoshikado, Takashi
    Toshimoto, Kota
    Sugiyama, Yuichi
    DRUG METABOLISM REVIEWS, 2015, 47 : 115 - 115
  • [45] Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
    Montanha, Maiara Camotti
    Fabrega, Francesc
    Howarth, Alice
    Cottura, Nicolas
    Kinvig, Hannah
    Bunglawala, Fazila
    Lloyd, Andrew
    Denti, Paolo
    Waitt, Catriona
    Siccardi, Marco
    CLINICAL PHARMACOKINETICS, 2022, 61 (03) : 375 - 386
  • [46] Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions
    Ishigam, M
    Uchiyama, M
    Kondo, T
    Iwabuchi, H
    Inoue, S
    Takasaki, W
    Ikeda, T
    Komai, T
    Ito, K
    Sugiyama, Y
    PHARMACEUTICAL RESEARCH, 2001, 18 (05) : 622 - 631
  • [47] The Impact and In Vitro to In Vivo Prediction of Transporter-Based Drug-Drug Interactions in Humans
    Unadkat, Jashvant D.
    Kirby, Brian J.
    Endres, Christopher J.
    Zolnerciks, Joseph K.
    ENZYME- AND TRANSPORTER-BASED DRUG-DRUG INTERACTIONS: PROGRESS AND FUTURE CHALLENGES, 2010, : 517 - 553
  • [48] Inhibition of In Vitro Metabolism of Simvastatin by Itraconazole in Humans and Prediction of In Vivo Drug-Drug Interactions
    Michi Ishigam
    Minoru Uchiyama
    Tomoko Kondo
    Haruo Iwabuchi
    Shin-ichi Inoue
    Wataru Takasaki
    Toshihiko Ikeda
    Toru Komai
    Kiyomi Ito
    Yuichi Sugiyama
    Pharmaceutical Research, 2001, 18 : 622 - 631
  • [49] Quantitative prediction of CYP3A4 drug-drug interactions: Extending the strategy
    Galetin, A
    Hallifax, D
    Ito, K
    Houston, JB
    DRUG METABOLISM REVIEWS, 2003, 35 : 62 - 62
  • [50] Quantitative prediction of drug-drug interactions: A comparison between microsomes and hepatocytes for azole-tolbutamide interactions
    Brown, HS
    Hallifax, D
    Houston, JB
    DRUG METABOLISM REVIEWS, 2003, 35 : 63 - 63
12345